(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Madan provided an assessment of a semi-automated method of assessing Sodium Fluoride (NaF) PET using a novel technology. This is particularly relevant given that current and emerging PET platforms are enhancing clinicians’ ability to evaluate metastatic lesions in mCRPC.